このページの翻訳は実験的なもので、現在開発中です。お待ちしております

ARS Pharmaceuticals マネジメント

マネジメント基準チェック /24

ARS Pharmaceuticals'の CEO はRich Lowenthalで、 Nov2022年に任命され、の在任期間は 1.75年です。の年間総報酬は$ 10.04Mで、 6.2%給与と93.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の5.94%を直接所有しており、その価値は$ 82.05M 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と3年です。

主要情報

Rich Lowenthal

最高経営責任者

US$10.0m

報酬総額

CEO給与比率	6.2%
CEO在任期間	1.8yrs
CEOの所有権	5.9%
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	3.1yrs

経営陣の近況

Recent updates

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

Sep 13

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Nov 14

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

May 12

CEO報酬分析

ARS Pharmaceuticals の収益と比較して、Rich Lowenthal の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$45m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$10m	US$620k	-US$54m
Sep 30 2023	n/a	n/a	-US$62m
Jun 30 2023	n/a	n/a	-US$53m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$909k	US$75k	-US$35m

報酬と市場: Richの総報酬 ($USD 10.04M ) は、 US市場 ($USD 5.62M ) の同規模の企業の平均を上回っています。

報酬と収益: Richの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Rich Lowenthal (58 yo)

1.8yrs

在職期間

US$10,039,096

報酬

Mr. Richard E. Lowenthal, also known as Rich, MS, MSEL, MBA, He serves as Director, Chief Executive Officer & President at ARS Pharmaceuticals, Inc. since November 08, 2022. He served as Head of Regulatory...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Richard Lowenthal	Founder	1.8yrs	US$10.04m	5.89% $ 81.8m
Sarina Tanimoto	Co-Founder & Chief Medical Officer	no data	US$4.79m	3.52% $ 48.8m
Alexander Fitzpatrick	Chief Legal Officer & Secretary	1.7yrs	US$5.32m	0.092% $ 1.3m
Robert Bell	Co-Founder & Chief Science Officer	no data	データなし	4.35% $ 60.3m
Kathleen Scott	Chief Financial Officer	2.4yrs	データなし	0.014% $ 189.1k
Brian Dorsey	Chief Operations Officer	no data	データなし	0.0062% $ 86.2k
Daniel Relovsky	Senior Vice President of Marketing	2.6yrs	データなし	データなし
Harris Kaplan	Executive Vice President of Commercial Strategy	2.6yrs	データなし	データなし
Eric Karas	Chief Commercial Officer	2.4yrs	US$618.61k	0.0059% $ 81.5k
Justin Chakma	Chief Business Officer & Secretary	1.8yrs	データなし	データなし

2.4yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: SPRYの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Richard Lowenthal	Founder	1.8yrs	US$10.04m	5.89% $ 81.8m
Phillip Schneider	Independent Director	no data	US$261.30k	0% $ 0
Pratik Shah	Chairman of the Board	no data	US$508.80k	4.98% $ 69.1m
Brenton L. Saunders	Director	3.3yrs	US$238.80k	0% $ 0
Rajeev Dadoo	Independent Director	3.1yrs	US$256.30k	データなし
Peter Kolchinsky	Independent Director	3.1yrs	US$253.80k	データなし
Saqib Islam	Independent Director	1.8yrs	US$250.05k	0.016% $ 218.2k
Thomas Casale	Member of Scientific Advisory Board	no data	データなし	データなし
Michael Kaliner	Member of Scientific Advisory Board	no data	データなし	データなし
Motohiro Ebisawa	Member of Scientific Advisory Board	no data	データなし	データなし
Michael Kelly	Independent Director	no data	US$248.80k	0.086% $ 1.2m
Richard Lockey	Member of Scientific Advisory Board	no data	データなし	データなし

3.1yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: SPRYの取締役会は経験豊富であると考えられます ( 3年の平均在任期間)。

ARS Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Founder exercised options to buy US$1.6m worth of stock.

Chief Legal Officer & Secretary recently bought US$320k worth of stock

Co-Founder & Chief Science Officer recently sold US$26m worth of stock

ARS Pharmaceuticals, Inc. Appoints Brian T. Dorsey as Chief Operations Officer

Recent updates

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval

ARS Pharmaceuticals, Inc. Launches Pre-Ordering Services for neffy to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals, Inc. Announces Approval of EURneffy (adrenaline nasal spray) in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

ARS Pharmaceuticals, Inc. Receives FDA Approval of Neffy® (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index

ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis)

ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles

First quarter 2024 earnings released: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)

ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Founder exercised options to buy US$1.6m worth of stock.

ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)

Consensus revenue estimates decrease by 19%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study

New minor risk - Profitability

Consensus revenue estimates decrease by 25%

Forecast to breakeven in 2026

ARS Pharmaceuticals, Inc. Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

Consensus EPS estimates upgraded to US$0.64 loss

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2022)

Chief Legal Officer & Secretary recently bought US$320k worth of stock

Consensus revenue estimates decrease by 99%, EPS upgraded

ARS Pharmaceuticals, Inc. Announces FDA Issues Complete Response Letter for neffy(R) (epinephrine nasal spray) New Drug Application with Request for Additional Study

Co-Founder & Chief Science Officer recently sold US$26m worth of stock

Second quarter 2023 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2022)

Consensus revenue estimates fall by 67%

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1Q 2022)

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings released

ARS Pharmaceuticals, Inc. Appoints Brian T. Dorsey as Chief Operations Officer

Chief Financial Officer recently bought US$52k worth of stock

No independent directors

ARS Pharmaceuticals, Inc. Announces Presentation of Clinical Data Supporting Neffy® for the Treatment of Allergic Reactions (Type I) Including Anaphylaxis

ARS Pharmaceuticals, Inc. Announces Board Changes

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24